Hubei Hvsen Biotechnology Co., Ltd. was established in 2009, a wholly-owned subsidiary of Wuhan Hvsen Biotechnology Co., Ltd. (stock code 300871). It covers an area of approximately 500 acres and has a total investment of 1.5 billion yuan (usd220 million). It is a national level high-tech enterprise specializing in animal health products. It is the main production base and research base of the group, covering multiple business sectors such as microbial fermentation, traditional Chinese medicine extraction, veterinary drug and aquatic products. The company has modern production equipment, advanced production technology and a comprehensive quality control system. As a responsible unit for projects such as the National Science and Technology Innovation Fund for Small and Medium sized Enterprises, Hubei Province Major New Products and Processes, and Hubei Province Major Science and Technology Innovation Plan (industrialization), Hubei Hvsen has been recognized as one of the leading enterprise in Hubei Province.
The company has been always at an advanced level in China in the research and development of the veterinary raw material drug “Tylvalosin Tartrate”. In 2014, the “Tylvalosin tartrate” project won the second prize for technological invention in Hubei Province. In 2017, the “Streptomyces hawaiiensis and its applications” won the Hubei Province Patent Excellence Award and the China Invention Patent Excellence Award.